Romiplostim for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (TA221)

Technology Appraisal Guidance No. 221

Source: National Institute for Health and Care Excellence

1. Guidance

1.1 Romiplostim is recommended for the treatment of adults with chronic immune (idiopathic) thrombocytopenia purpura:

  • whose condition is refractory to standard active treatments and rescue therapies or
  • who have severe disease and a high risk of bleeding that needs frequent courses of rescue therapies
  • if the manufacturer makes romiplostim available with the discount agreed as part of the patient access scheme.

1.2 Only a haematologist should start and supervise treatment with romiplostim.

The guidance shown above constitutes Section 1 of the full document. A copy of the full document and a summary of the evidence is available on the Internet at

An abridged version of this guidance (a 'quick reference guide') is also available. Printed copies of the quick reference guide can be obtained by contacting 0845 003 7783 or emailing and quoting reference number N2521. It is also available on the Internet at

This guidance represents the view of the Institute which was arrived at after careful consideration of the available evidence. Health professionals are expected to fully take it into account when exercising their clinical judgement. This guidance does not, however, override the individual responsibility of health professionals to make appropriate decisions in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

© Copyright National Institute for Health and Care Excellence. All rights reserved. This material may be freely reproduced for educational and not for profit purposes within the NHS. No reproduction by or for commercial organisations is permitted without the express written permission of the Institute.

Enquiries concerning the guidance should be addressed to: National Institute for Health and Care Excellence, MidCity Place, 71 High Holborn, London WC1V 6NA. email:

Romiplostim for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura
Issue Date: April 2011

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in